Loading news...
Xencor, Inc. (XNCR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten research firms that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the
Xencor, Inc. (NASDAQ: XNCR - Get Free Report)'s stock price gapped down before the market opened on Thursday after an insider sold shares in the company. The stock had previously closed at $12.74, but opened at $11.85. Xencor shares last traded at $11.53, with a volume of 514,772 shares trading hands. Specifically, CEO Bassil I. Dahiyat
On Wednesday, Xencor Inc. (NASDAQ: XNCR) said it is revising its revenue outlook for royalties tied to Ultomiris.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the “Licensee”) informed Xencor, Inc. (the “Company”) that it has taken the position that the Licensee does not owe any additional royalties for sales of Ultomiris® (ravulizumab-cwvz) in the United States and that the Licensee does not intend to make any.
Xencor (XNCR) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.62 per share a year ago.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025. “Xencor's lead oncology drug candidate is XmAb819, a novel first-in-class T-cell engager that could offer a much-needed new therapeutic modality for patients with advanced clear cell renal cell carcinoma (ccRCC).
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen 46th Annual Health Care Conference Date: Monday, March 2, 2026 Presentation Time: 3:50 p.m. ET / 12:50 p.m. PT Leerink Partners 2026 Global Healthcare Conference Date: Tuesday, March 10, 2026 Presen.
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. The average
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) passed below its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $12.41 and traded as low as $11.76. Xencor shares last traded at $11.99, with a volume of 471,276 shares traded. Analyst Ratings Changes
Shares of Xencor, Inc. (NASDAQ: XNCR - Get Free Report) crossed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $15.41 and traded as low as $12.50. Xencor shares last traded at $13.02, with a volume of 641,201 shares changing hands. Wall Street Analyst Weigh
Xencor, Inc. (NASDAQ: XNCR - Get Free Report) has earned an average rating of "Moderate Buy" from the ten research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026 pipeline advancement milestones for its clinical-stage portfolio of novel XmAb® drug candidates. “Xencor designs proteins that enable potential first-in-class and best-in-class medicines for patients, and we are building on momentum from 2025, when we presented.
XNCR pairs a wholly owned antibody pipeline with XmAb platform partnerships. This way, they get milestones, licensing revenue, and royalties. This approach lets them partially fund their internal R&D. But on top of that, XNCR has ample liquid resources it can tap into as needed. XNCR's lead immunology asset XmAb942 is in Phase 2b for ulcerative colitis. And this candidate could help validate their ability to advance late-stage assets internally.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the issuance of U.S. Patent 12,492,253, which covers Xencor's Xtend™ Fc domain for extending the half-life of antibodies targeting C5, with a term that extends into December 2028. The new patent term is approximately three years longer than the previous latest-to-expire U.S. patent covering.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences: TD Cowen Immunology and Inflammation Virtual Summit Date: Wednesday, November 12, 2025 Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT Piper Sandler 37th Annual Healthcare Conference Date: Tuesday, December.
Y Intercept Hong Kong Ltd grew its position in shares of Xencor, Inc. (NASDAQ: XNCR) by 93.0% in the second quarter, according to its most recent filing with the SEC. The fund owned 95,745 shares of the biopharmaceutical company's stock after acquiring an additional 46,140 shares during the quarter. Y Intercept Hong Kong
Xencor (XNCR) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.71 per share a year ago.
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025 and provided recent business and clinical program updates. “Xencor's two novel, first-in-class, CD3 T-cell engaging bispecific antibodies, XmAb819 and XmAb541, have demonstrated compelling clinical data in advanced clear cell r.
Xencor (NASDAQ: XNCR - Get Free Report) is expected to post its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect Xencor to post earnings of ($0.72) per share and revenue of $29.7290 million for the quarter. Individuals can find conference call details on the company's upcoming Q3 2025 earningreport page for